Telix Pharmaceuticals Ltd
TLX$2.59B
Mid CapNASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
6
Phase 3 Programs
5
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
TLX News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
Standard of Care
Metastatic Prostate Cancer
177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer
68Ga-PSMA-11
Biochemical Recurrence of Malignant Neoplasm of Prostate
89Zr-TLX250 PET/CT
Clear Cell Renal Cell Carcinoma
Enzalutamide
Metastatic Castration-resistant Prostate Cancer
177Lu-DOTA-TLX591
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard of Care | Phase 3 | Metastatic Prostate Cancer | - | - |
177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
68Ga-PSMA-11 | Phase 3 | Biochemical Recurrence of Malignant Neoplasm of Prostate | - | - |
89Zr-TLX250 PET/CT | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Enzalutamide | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply